You are currently on the new version of our website. Access the old version .
MDPIMDPI
Search all articles
MedicinaMedicina
Download PDF
  • Case Report
  • Open Access

22 April 2023

Spontaneous Improvement of Aortitis Associated with Severe COVID-19 Infection—A Case Report

,
,
and
1
Division of Emergency and Disaster Medicine, Tohoku Medical and Pharmaceutical University Hospital, 1-15-1, Fukumuro, Miyaginoku, Sendai City 983-8512, Miyagi, Japan
2
Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital, 1-15-1, Fukumuro, Miyaginoku, Sendai City 983-8512, Miyagi, Japan
*
Author to whom correspondence should be addressed.
Medicina2023, 59(5), 816;https://doi.org/10.3390/medicina59050816
Version Notes
Order Reprints
Review Reports

Abstract

Aortitis is a rare complication of the coronavirus disease 2019 (COVID-19) and is often treated empirically with steroids. We present a case of spontaneous resolution of aortitis without treatment. A 65-year-old man was admitted to our intensive care unit for severe COVID-19 pneumonia and underwent rehabilitation in the general ward. On day 12, he developed fever, and on day 13, he developed right cervical pain and increased inflammatory markers. On day 16, a cervical echocardiogram showed vasculitis in the right common carotid artery, and on day 17, computed tomography (CT) of the neck showed thickening of the arterial wall of the right common to the internal carotid arteries. A retrospective assessment of the CT scan on day 12 showed wall thickening from the thoracic aorta to the abdominal aorta, and a diagnosis of aortitis was made. Autoantibody analysis, culture, and magnetic resonance imaging (MRI) of the head and neck showed no abnormalities. During the investigation of the cause of aortitis, the fever and inflammatory reaction spontaneously resolved and the right cervical pain gradually improved. Therefore, the patient was diagnosed with transient COVID-19-related aortitis. To our knowledge, this is the first report describing the spontaneous resolution of COVID-19-related aortitis.

1. Introduction

Coronavirus disease 2019 (COVID-19) is a viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first reported in Wuhan, China on 31 December 2019, and subsequently became a global pandemic. Common symptoms of COVID-19 include cough (50%), fever (43%), myalgia (36%), headache (34%), and respiratory distress (28.5%) [1]. Other reported complications include taste and smell disorders, myocarditis, encephalitis, and vascular events such as myocardial infarction, pulmonary embolism, and cerebral infarction [1,2]. Although rare, vasculitis and aortitis have also been reported to be complications of COVID-19 and are usually treated with steroids. In the present case, three weeks after the COVID-19 infection, the patient developed aortitis with fever and neck pain that resolved spontaneously without any specific drug treatment. To the best of our knowledge, no case of spontaneously resolving COVID-19-associated aortitis has been reported to date, and this is the first report describing such a case.

2. Case Presentation

A 65-year-old Japanese man was brought to our hospital with severe dyspnea. Nine days before visiting our hospital, he had developed a sore throat, fever, and cough. He tested positive for the COVID-19 antigen at home and was prescribed an antipyretic analgesic (acetaminophen) and expectorant (ambroxol/l-carbocysteine) by his family clinic the next day. Six days prior to his visit, his dry coughing symptoms worsened, and headache and dyspnea also appeared; he was admitted to another hospital one day before visiting our hospital. The oxygen saturation (SpO2) was 93% (room air) on admission, but soon after admission, it dropped to the 80% range even with an oxygen mask at 5 L/min. He was switched to a high-flow nasal cannula (HFNC), and the SpO2 increased to 90–92% at a flow rate of 40 L/min and a fraction of inspired oxygen (FiO2) value of 60%. The blood gas analysis showed the following findings: pH, 7.46; partial pressure of oxygen (PO2), 78.8; and partial pressure of carbon dioxide (PCO2), 36.6. The treatment included remdesivir 200 mg/day and methylprednisolone 1000 mg/day for COVID-19 pneumonia, tazobactam/piperacillin 4.5 g three times/day for bacterial infection complications, and heparin 15,000 units/day for thromboprophylaxis. However, the previous physician was unable to cope with the rapid worsening of the patient’s respiratory condition, and he was transferred to the intensive care unit of our hospital.
The patient’s medical history included hypertension, and he was taking amlodipine (5 mg). His vital signs on arrival were as follows: blood pressure, 177/92 mmHg; pulse, 97 bpm; respiratory rate, 25 breaths/min; SpO2, 93–95% (HFNC; flow: 60 L/min and FiO2: 60%); and body temperature, 36.8 °C. Arterial blood gas analysis showed the following findings: PaO2, 81.8 mmHg; PCO2, 34.6 mmHg; HCO3−, 23.2 mmol/L; lactate level, 3.6 mmol/L; and P/F, 136. Blood tests revealed slightly elevated levels of liver enzymes (aspartate aminotransferase, 70 U/L; alanine transaminase, 49 U/L; and lactate dehydrogenase, 487 U/L), increased inflammatory response (C-reactive protein (CRP), 188 mg/L), and impaired coagulation (activated partial thromboplastin time > 200 s; prothrombin time/international normalized ratio, 1.4; antithrombin III, 68%; and D-dimer, 1.88 µg/mL) (Table 1). Chest computed tomography (CT) showed a bilateral diffuse ground-glass appearance with infiltrative shadows just below the pleura (Figure 1). The patient was treated with remdesivir, dexamethasone (for 10 days), tazobactam/piperacillin, and heparin. On day seven of hospitalization, he was transferred from the intensive care unit to the general ward for rehabilitation.
Table 1. Blood test at the time of arrival.
Figure 1. CT image showing extensive frosted shadows and sclerotic images in both lungs.
However, on day 12 of hospitalization, the patient developed a fever of 38.1 °C. To investigate the source of the fever, blood tests, urinalysis, blood culture, and contrast-enhanced CT scans of the neck, thorax, abdomen, and pelvis were performed. Blood tests showed a white blood cell (WBC) count of 14.4 × 103/μL (neutrophils: 79.0%, lymphocytes: 4.0%, monocytes: 17.0%, basophils: 0%, and eosinophils: 0%) and a CRP level of 290 mg/L, while the urinalysis showed positive results for white blood cells and nitrite. Contrast-enhanced CT revealed no abnormalities in the renal parenchyma. However, based on the urinalysis and elevated inflammatory response, we considered the possibility of a urinary tract infection and started 500 mg levofloxacin on the same day. However, the antimicrobial agents did not relieve the fever, and the right cervical pain newly appeared on day 13 of hospitalization. A central venous catheter was inserted through the right internal jugular vein from the day of admission to day eight; we considered the possibility of infectious thrombophlebitis and performed neck echocardiography on day sixteen of hospitalization. A neck ultrasound showed a hypoechoic area (Figure 2) surrounding the right common carotid artery, which was suspected to indicate vasculitis. On day 17 of hospitalization, contrast-enhanced CT of the neck showed wall thickening and increased periprosthetic fatty tissue density in the right common, internal, and external carotid arteries, especially in the right internal carotid artery, with narrowing of the lumen (Figure 3).
Figure 2. Echocardiographic image showing a hypoechoic region surrounding the right common carotid artery (red arrow).
Figure 3. CT image showing thickening of the right internal (red arrow), external (yellow arrow), and common carotid artery (blue arrow) and narrowing of the internal carotid artery.
Based on these results, contrast-enhanced CT was performed on day 12 of hospitalization, and wall thickening (Figure 4) was observed from the thoracic aorta to the abdominal aorta. Aortitis was diagnosed based on these results, and a close examination of the cause was conducted. Immunological tests showed negative results for rheumatoid factor, anti-nuclear antibody, whole anti-Sm antibody, anti-RNP antibody, anti-ds DNA antibody, anti-SS-A body, anti-SS-B body, anti-neutrophil cytoplasmic antibody (ANCA), whole MPO-ANCA and C-ANCA, and anti-cardiolipin IgG antibody. The complement levels were elevated (C3, 1910 mg/L; C4, 390 mg/L; and CH50, >600 U/L). The blood culture, syphilis test, tests for hepatitis B and C, HIV test, parvovirus, interferon-gamma release assays (IGRA), and tests for other infectious vasculitis all showed negative results. The procalcitonin level was also not elevated (0.04 ng/mL). Contrast-enhanced MRI of the head and neck showed no obvious wall thickening of the temporal artery, and the cerebral arteries were well-defined. Based on these results, the cause of aortitis was considered to be COVID-19.
Figure 4. CT image with the red arrowhead indicating thickening of the thoracic to the abdominal aorta.
The CRP level gradually decreased from day 16 of hospitalization, reaching 86 mg/L on day 20 of hospitalization. The fever resolved accordingly, and the right cervical pain also improved. No steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) were administered during this period. The patient’s condition continued to improve and he was discharged on day 21 of hospitalization. An outpatient assessment performed 2 days after discharge showed that the right cervical pain had completely disappeared, and the CRP level had decreased to 32 mg/L. Based on these findings, a diagnosis of transient aortitis due to COVID-19 was made. When the patient was discharged from the hospital 14 days later, his CRP level had further decreased to 9 mg/L, and he showed no recurrence of neck pain. Ophthalmological examination on the same day revealed no findings suggestive of giant cell arteritis.

3. Discussion

We encountered a case of aortitis that was diagnosed due to the appearance of fever and neck pain 3 weeks after the onset of COVID-19. To the best of our knowledge, this is the first case describing the spontaneous resolution of COVID-19-associated aortitis.
Aortitis is a pathological term for all diseases that cause inflammation of the aortic wall, which can be non-infectious or infectious in origin [3,4]. The most common non-infectious causes are Takayasu arteritis (TKA) and giant cell arteritis (GCA) [3,4]. Infectious causes include hepatitis viruses (mainly types B and C), parvovirus, syphilis, tuberculosis, Gram-positive cocci (Staphylococcus aureus, Enterococcus faecalis, Streptococcus pneumoniae), and Gram-negative rods (Salmonella spp.) [3,4]. In the present case, these infectious diseases were ruled out because the infectious disease tests (blood culture, syphilis test, IGRA, hepatitis B, hepatitis C, and parvovirus) showed negative results. Based on the course of the disease, we considered aortitis due to COVID-19, but it was necessary to differentiate between TKA and GCA, both of which are distinguished on the basis of the widely used classification criteria developed by the American College of Rheumatology (ACR) [5,6]. The ACR classification criteria for TKA are as follows: (1) age of onset before 40 years, (2) claudication of the extremities, (3) brachial artery pulsatility, (4) difference in brachial blood pressure > 10 mmHg, (5) vascular murmur in the subclavian artery or aortic arch, and (6) angiographic evidence of stenosis or obstruction in the aorta, its branches, or the large arteries in the limbs [5]. When three or more of the above six criteria are met, the patient is diagnosed with TKA. However, in the present case, the patient did not fulfill the four criteria: age > 40 years, no claudication of the extremities, no weakening of the brachial artery, and no vascular murmur, so the diagnosis of TKA was not made. On the other hand, the ACR classification criteria for GCA are as follows: (1) age > 50 years, (2) new-onset headache, (3) tenderness in the temporal artery or decreased pulse unrelated to atherosclerosis, (4) erythrocyte sedimentation rate > 50 mm/h, and (5) vasculitis with mononuclear cell infiltration, granulomatous inflammation, or multinucleated giant cells in a biopsy specimen of the shallow temporal artery [6]. When three or more of the five criteria are met, GCA is diagnosed. In the present case, only two criteria could be ruled out: the absence of new-onset headache and the absence of tenderness in the temporal artery. However, the MRI showed no arteritis in the temporal artery. Therefore, typical “cranial” GCA was ruled out. GCA includes “cranial” GCA and “large-vessel” GCA [7], but “large-vessel” GCA was not excluded. However, GCA requires steroid therapy, and spontaneous improvement and no recurrence after discharge from the hospital do not fit the course of GCA. Based on these findings, we diagnosed aortitis caused by COVID-19.
The mechanism underlying COVID-19-induced aortitis is not yet fully understood. However, Bellosta et al. [8] described the following pathophysiology of thrombosis in small- to medium-sized arteries in COVID-19 patients. First, endothelial cells are infiltrated by virions, which are then infiltrated by neutrophils and mononuclear elements, leading to accelerated apoptosis and lymphoid endotheliitis and resulting in an inflammatory and thrombotic environment. In the later stages of the disease, the same inflammatory elements expand and infiltrate the same arteries, causing periarteritis, followed by leukocytoclastic vasculitis. This reaction is followed by the deposition of antigen–antibody immune complexes, IgG, IgA, and IgM, resulting in type III hypersensitivity vasculitis. These conditions can also occur in large blood vessels such as the aorta [9]. Inflammation near the heart can cause arrhythmia, as seen in cases where inflammation at the base of the aorta caused an atrioventricular block, which in turn leads to life-threatening ventricular tachycardia caused by bundle branch reentry ventricular tachycardia (BBRVT) [10]. The aortic endothelium is largely composed of angiotensin-converting enzyme 2 (ACE2) receptors, and SARS-CoV-2 is thought to invade cells via these ACE2 receptors and cause endotheliitis and leukocytoclastic vasculitis, in addition to type 3 hypersensitivity vasculitis [4].
Aortitis after COVID-19 has been previously reviewed by Hassan et al. [11], and several cases have been reported since. Seven cases of aortitis secondary to COVID-19, including our case, were included in our review (Table 2) [4,12,13,14,15,16]. The age at onset in these cases ranged from 19 to 73 years (median: 61 years), and the condition was more common in males. The symptoms varied, but the site of inflammation was associated with symptoms, e.g., abdominal pain if the site of inflammation was the infrarenal aorta. The onset of symptoms may occur at the same time as COVID-19 or two months later; therefore, it is impossible to specify a specific onset time. Since aortitis does not allow for invasive tests such as a biopsy, the diagnosis is made by CT. Diagnostic blood markers have not yet been established, but CRP, erythrocyte sedimentation rate (ESR), and interleukin-6, an inflammatory cytokine, tend to be elevated [4,17]. IgG4 is considered less relevant. Steroids (prednisolone) are often the initial treatment of choice for aortitis. Initial doses are based on the European League Against Rheumatism (EULAR) initial doses for large-vessel arteritis (GCA and TKA) and are often 0.8–1 mg/kg of prednisolone [4]. In GCA and TKA, once the disease is under control, the goal is to reduce the dose of prednisolone to 15–20 mg/day within 2–3 months, and after 1 year, to less than 5 mg/day for GCA and less than 10 mg/day for TKA [18]. However, the rate of reduction of prednisolone for aortitis caused by COVID-19 has not been determined. The only report on this topic was presented by Joao et al. [12]. Another case report described the treatment of a patient with NSAIDs instead of steroids [15]. NSAID-treated patients had a slightly longer time for symptoms or laboratory improvement than steroid-treated patients (3–14 days for steroids and 24 days for NSAIDs).
The present case involved a 65-year-old man who showed aortitis 3 weeks after COVID-19. His symptoms included fever and right neck pain, and the CT showed wall thickening of the right internal carotid artery, common carotid artery, and thoracoabdominal aorta. The findings in the right common carotid artery were particularly strong and seemed to be related to right neck pain. Blood tests revealed elevated CRP, ESR, and interleukin-6 levels. However, the case differed from previous cases since the patient received no steroids or NSAIDs. Under normal circumstances, the time to the improvement of symptoms or tests in a spontaneously resolving case would seem to be longer than that in cases treated with steroids or NSAIDs, but this case showed an improvement in 11 days, which was not different from that in steroid-treated cases (Table 2).
Table 2. Cases of aortitis after coronary infection, including this case.
Table 2. Cases of aortitis after coronary infection, including this case.
ReferenceSexAgePast Medical HistorySymptomsTime from COVID-19 Onset to Dx of AortitisArteritis LocationMode of DxCRP
(mg/L)		ESR
(mm/h)		IL-6
(ng/L)		IgG4
(mg/dL)		Aortitis RxTime to ImprovementDuration of RxOutcome
Dhakal et al. [4]M63PD/asthma/DM/HTN/obesity
/non-ischemic cardiomyopathy		Diffuse abdominal pain,
dry cough,
fatigue, and generalized weakness		Concurrent with COVID19 onsetInfrarenal aortaCT875754187Prednisolone 60 mg9 days1 monthDischarge
Mendes et al. [12]F19NoneGeneral fatigue,
malaise, and chest and low back pain 		1 month Descending thoracic and abdominal aortaCT/
FDGPET		107109-55Prednisolone 60 mg3 daysReduce dose by 5 mg every two weeks → About 6 monthsDischarge
Shergill et al. [13]M71NoneExtreme fatigue, poor appetite with 5 kg weight loss, and a sharp left-sided chest pain radiating to his scapula2 monthsSubclavian arteries to the iliac bifurcationCT185-28-Prednisolone 40 mg2 weeksMore than 2 weeks (End period unknown)Discharge
Zou and Vasta [14]M71Cholecystectomy, rotator cuff repairFeeling generally unwell, weight loss, and worsening thoracolumbar back pain2 monthsAortic arch extending all the way down the aorta CT122-25-Prednisolone 40 mg1 weekMore than 2 weeks (End period unknown)Discharge
Oda et al. [15]M71NoneFever and productive cough2 weeksAbdominal aorta to the bilateral common iliac arteriesCT17761-112NSAIDs24 days1 monthDischarge
Kobe et al. [16]M72DMDyspnea and pain in the left lower legConcurrent with COVID19 onsetAbdominal aorta to the left common iliac arteryCT315---Unknown--Death
Shimada et al. (this case)M65HTNFever and right cervical pain3 weeksAortic arch to right common carotid artery and right internal carotid arteryCT2806318.324None11 days-Discharge
CRP, C-reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; FDG-PET, fluorodeoxyglucose-positron emission tomography; IL-6, interleukin 6; NSAIDs, nonsteroidal anti-inflammatory drugs; PD, Parkinson disease; DM, Diabetes mellitus; HTN, Hypertension; -; Not mentioned in the article.

4. Conclusions

We encountered a case of aortitis caused by severe COVID-19 pneumonia that improved without the administration of steroids or NSAIDs. However, as the initial dose of steroids and the rate of dose reduction were not recorded and some patients improve without steroids, as in this case, the accumulation of data from additional case reports is needed, and the treatment options should be carefully considered.

Author Contributions

Conceptualization, T.S. and H.I.; methodology, T.S. and H.I.; validation T.S. and H.I.; investigation, T.S. and H.I.; writing—original draft preparation, T.S. and H.I.; writing—review and editing, Y.S. and T.E. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was approved by the Institutional Review Board of Tohoku Medical and Pharmaceutical University Hospital 2022-4-063/approval date 22 February 2023.

Data Availability Statement

The data that were presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy restrictions.

Acknowledgments

We would like to express our sincere gratitude to Meya Asahi, Takashi Matsumura, and Yoshinobu Abe for their assistance in treating patients.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Stokes, E.K.; Zambrano, L.D.; Anderson, K.N.; Marder, E.P.; Raz, K.M.; El Burai Felix, S.; Tie, Y.; Fullerton, K.E. Coronavirus Disease 2019 Case Surveillance—United States, 22 January–30 May 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 759–765. [Google Scholar] [CrossRef] [PubMed]
  2. Katsoularis, I.; Fonseca-Rodríguez, O.; Farrington, P.; Lindmark, K.; Connolly, A.-M.F. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: A self-controlled case series and matched cohort study. Lancet 2021, 398, 599–607. [Google Scholar] [CrossRef] [PubMed]
  3. Katabathina, V.S.; Restrepo, C.S. Infectious and Noninfectious Aortitis: Cross-Sectional Imaging Findings. Semin. Ultrasound CT MRI 2012, 33, 207–221. [Google Scholar] [CrossRef]
  4. Dhakal, P.; Khadka, S.; Clowes, J.A.; Chakinala, R.C. Aortitis in COVID-19. IDCases 2021, 24, e01063. [Google Scholar] [CrossRef]
  5. Arend, W.P.; Michel, B.A.; Bloch, D.A.; Hunder, G.G.; Do, L.H.C.; Edworthy, S.M.; Fauci, A.S.; Leavitt, R.Y.; Lie, J.T.; Jr, R.W.L.; et al. The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis. Arthritis Rheum. 1990, 33, 1129–1134. [Google Scholar] [CrossRef] [PubMed]
  6. Hunder, G.G.; Bloch, D.A.; Michel, B.A.; Stevens, M.B.; Arend, W.P.; Do, L.H.C.; Edworthy, S.M.; Fauci, A.S.; Leavitt, R.Y.; Lie, J.T.; et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990, 33, 1122–1128. [Google Scholar] [CrossRef] [PubMed]
  7. Brack, A.; Martinez-Taboada, V.; Stanson, A.; Goronzy, J.J.; Weyand, C.M. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999, 42, 311–317. [Google Scholar] [CrossRef]
  8. Bellosta, R.; Luzzani, L.; Natalini, G.; Pegorer, M.A.; Attisani, L.; Cossu, L.G.; Ferrandina, C.; Fossati, A.; Conti, E.; Bush, R.L.; et al. Acute limb ischemia in patients with COVID-19 pneumonia. J. Vasc. Surg. 2020, 72, 1864–1872. [Google Scholar] [CrossRef]
  9. Manenti, A.; Farinetti, A.; Manco, G.; Mattioli, A. Vasculitis and aortitis: COVID-19 challenging complications. J. Vasc. Surg. 2021, 73, 347–348. [Google Scholar] [CrossRef]
  10. Melchior, S.E.; Schoos, M.M.; Gang, U.; Jacobsen, P.K.; Wiese, L.; Melchior, T.M. Recurring episodes of bundle branch reentry ventricular tachycardia due to aortitis preceded by SARS-CoV-2 infection: A case report. BMC Cardiovasc. Disord. 2023, 23, 46. [Google Scholar] [CrossRef]
  11. Abu Hassan, F.; Abu Alhalawa, M.; Majdoubeh, Y.; Nepal, A.; Sufan, S.S. COVID-19 Aortitis: A Review of Published Cases. Cureus 2022, 14, e22226. [Google Scholar] [CrossRef] [PubMed]
  12. Mendes, J.L.; Venade, G.; Manuel, P.; Matos, L.C.; Nascimento, E. Virus and Autoimmunity: Can SARS-CoV-2 Trigger Large Vessel Vasculitis? Eur. J. Case Rep. Intern. Med. 2022, 9, 003486. [Google Scholar] [CrossRef] [PubMed]
  13. Shergill, S.; Davies, J.; Bloomfield, J. Florid aortitis following SARS-CoV-2 infection. Eur. Hear. J. 2020, 41, 4286. [Google Scholar] [CrossRef] [PubMed]
  14. Zou, Y.; Vasta, B. EP14 COVID-19 Associated Aortitis. Rheumatol. Adv. Pract. 2020, 4, rkaa052.013. [Google Scholar] [CrossRef]
  15. Oda, R.; Inagaki, T.; Ishikane, M.; Hotta, M.; Shimomura, A.; Sato, M.; Nakamoto, T.; Akiyama, Y.; Yamamoto, K.; Minamimoto, R.; et al. Case of Adult Large Vessel Vasculitis after SARS-CoV-2 Infection. Ann. Rheum. Dis. 2020, 82, e25. [Google Scholar] [CrossRef] [PubMed]
  16. Kobe, H.; Ito, A.; Ishida, T. COVID-19-induced Adult Multisystem Inflammatory Syndrome and Fatal Acute Limb Ischaemia. Respirol. Case Rep. 2021, 10, e0886. [Google Scholar] [CrossRef] [PubMed]
  17. Wong, K.; Alam Shah, M.U.F.; Khurshid, M.; Ullah, I.; Tahir, M.J.; Yousaf, Z. COVID-19 associated vasculitis: A systematic review of case reports and case series. Ann. Med. Surg. 2022, 74, 103249. [Google Scholar] [CrossRef] [PubMed]
  18. Hellmich, B.; Agueda, A.; Monti, S.; Buttgereit, F.; de Boysson, H.; Brouwer, E.; Cassie, R.; Cid, M.C.; Dasgupta, B.; Dejaco, C.; et al. 2018 Update of the EULAR Recommendations for the Management of Large Vessel Vasculitis. Ann. Rheum. Dis. 2019, 79, 19–30. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View
Previous
The Psychological Antecedents to COVID-19 Vaccination among Community Pharmacists in Khartoum State, Sudan
Next